Bass’ New Buy – ZIOPHARM Oncology Inc.
The new position is a company called ZIOPHARM Oncology Inc. (ZIOP). Bass bought 316,987 shares at an average price of $4. He also bought and sold a smaller parcel of shares of the company in the first and second quarter of 2012.
ZIOPHARM Oncology Inc. is a Delaware Corporation. It is a biopharmaceutical company engaged in the development and commercialization of small molecule and synthetic biology approaches to new cancer therapies. The drug in the latest stage is Palifosfamide (ZIO-201) which is a type of drug called alkylating agents that binds to cancer cell DNA to halt tumor growth. It is currently in Phase 3 studies.
Ziopharm Oncology Inc. has a market cap of $144.6 million; its shares were traded around $1.76 with and P/S ratio of 176.50.
Other Gurus who bought the stock in the fourth quarter include: Jean-Marie Eveillard, Paul Tudor Jones and Steven Cohen.
See Kyle Bass’ portfolio here. Also check out the Undervalued Stocks, Top Growth Companies and High Yield stocks of Kyle Bass.